GH / IGF research comparison
CJC-1295 With DAC vs Without DAC
An identity-first comparison explaining why the classic long half-life data for albumin-binding CJC-1295 cannot be assigned to products marketed as “CJC-1295 without DAC.”
Editorial answer
The short answer
These names do not describe interchangeable materials. The 5.8–8.1 day human half-life estimate belongs to the albumin-binding DAC form studied by Teichman and colleagues.
Research and evidence interpretation only. No usage or dosing guidance.Structured comparison
Compare like with like
Every difference includes an interpretation note so a molecular or protocol distinction is not converted into a marketing claim.
Swipe horizontally to compare every column
| Question | CJC-1295 With DAC | CJC-1295 Without DAC | Editorial interpretation |
|---|---|---|---|
| Identity convention | CJC-1295 carrying the reactive Drug Affinity Complex group used for albumin conjugation | Commercial term generally used for a non-albumin-binding modified GRF(1-29)-type peptide | “Without DAC” is a market convention and needs sequence-level specification. |
| Exposure design | Covalent albumin binding extends exposure | No DAC albumin-binding group; short-peptide behavior must be established for the exact sequence | Do not transfer pharmacokinetics between the two forms. |
| Human pharmacokinetic evidence | Estimated half-life 5.8–8.1 days in early controlled studies | No product-specific public human pharmacokinetic record identified for the catalog naming convention | Absence of evidence should be displayed, not replaced with the DAC number. |
| Human research context | Early randomized healthy-volunteer GH/IGF-1 pharmacodynamic studies | Older GRF(1-29) and analogue studies provide pathway context | Pathway similarity is not identity equivalence. |
| Regulatory status | No FDA-approved CJC-1295 finished medicine | No FDA-approved “CJC-1295 without DAC” finished medicine | Research-use catalog status remains distinct from clinical development. |
Evidence cards
What the linked records actually report
Findings remain attached to the study population, experimental model and source type.
Two randomized, placebo-controlled ascending-dose studies reported sustained GH/IGF-1 effects and a 5.8–8.1 day estimated half-life.
The tested material was the long-acting albumin-binding CJC-1295 form.Open source ↗A later healthy-men study examined GH pulsatility one week after CJC-1295 exposure.
It does not test the commercial “without DAC” naming convention.Open source ↗Human GRF(1-29) studies establish that short fragments can retain GH-releasing activity.
They do not identify or validate a particular catalog without-DAC material.Open source ↗Translation boundary
What this comparison cannot establish
- That “without DAC” has the same half-life as albumin-binding CJC-1295.
- That older GRF(1-29) studies verify a modern catalog sequence or lot.
- That endocrine biomarker changes establish body-composition or anti-aging outcomes.
Sources
References used for this comparison
- 01Human randomized studies
Prolonged stimulation of GH and IGF-I secretion by CJC-1295
Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683.
- 02Human study
Pulsatile GH secretion persists during CJC-1295 stimulation
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006. PMID 17018654.
- 03Human study
GRF1-29 compared with longer human GRF fragments
Losa M, et al. Klin Wochenschr. 1984. PMID 6240568.
- 04Analogue design
Potent long-acting GRF analogues
Rivier J, et al. Ann N Y Acad Sci. 1988. PMID 3133968.
Editorial analysis
Read the product-specific source reviews
These articles expand individual identity, trial and evidence questions without changing the comparison conclusions above.
CJC-1295 With DAC in Healthy Adults: GH, IGF-1 and Half-Life Data
The classic CJC-1295 human paper evaluated a long-acting albumin-binding analog in healthy adults. Its sustained hormone profile is evidence for the DAC form studied—not…
Read source review →CJC-1295 With DAC: Albumin Binding, Identity Controls and FDA Safety Context
For CJC-1295 with DAC, the albumin-reactive group is not a branding detail. It changes persistence, analytical behavior and the relevance of the published human…
Read source review →CJC-1295 Without DAC: Why the Classic Long-Acting Trial Does Not Apply
The best-known CJC-1295 human studies tested an albumin-binding DAC construct. A product labeled “CJC-1295 without DAC” lacks that defining feature, so quoting the 5.8–8.1…
Read source review →CJC-1295 Without DAC: Sequence, Naming and a Quality Checklist
The phrase “without DAC” tells the reader what is absent, but it may not fully tell them what is present. Reproducible research requires an…
Read source review →Comparison FAQ
Questions this page is designed to answer
Can the 5.8–8.1 day half-life be used for CJC-1295 without DAC?
No. That estimate comes from studies of the albumin-binding DAC form.
Is “CJC-1295 without DAC” a precise scientific identity?
Not by itself. The label is used commercially for modified GRF(1-29)-type materials; the exact sequence and form need a product specification.
Continue researching